Chronic Pain Treatment Market Size Share Growth & Forecast 2023-2030

Global Chronic Pain Treatment Market Set to Surge, Projected to Reach US$ 143.2 Billion by 2030

Market Overview

In a remarkable growth trajectory, the Global Chronic Pain Treatment Market soared to US$ 83.8 billion in 2022 and is poised to achieve a staggering US$ 143.2 billion by 2030, indicating a robust Compound Annual Growth Rate (CAGR) of 7.1% during the forecast period from 2023 to 2030. Chronic pain, encompassing ailments such as migraines, back pain, arthritis, and neuropathic pain, is a pervasive health concern globally. Treatment modalities involve pharmaceuticals and innovative devices designed to enhance patient outcomes.

Market Scope and Metrics

CAGR: 7.1%
Size Available for Years: 2021-2030
Forecast Period: 2023-2030
Data Availability: Value (US$)
Segments Covered: Product Type, Indication, Distribution Channel
Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Fastest Growing Region: Asia-Pacific
Largest Region: North America
Report Insights Covered: Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other Key Insights.

Download Sample: https://www.datamintelligence.com/download-sample/chronic-pain-treatment-market

Market Dynamics:

The surge in FDA approvals for neurostimulation devices emerges as a pivotal driver for the global chronic pain treatment market. Neuspera Medical, a US-based neuromodulation devices maker, recently received FDA approval for its Neuspera ultra-miniaturized system, revolutionizing peripheral nerve stimulation with a wireless, less invasive, and versatile platform.

Furthermore, the landscape sees a surge in clinical trials, such as Tufts University's exploration of immersive virtual reality as a treatment for chronic back pain. However, the complexities associated with neuropathic pain diagnosis and treatment pose challenges to market growth, emphasizing the need for accurate diagnostics and periodic reassessment of treatment approaches.

Segment Analysis:

The chronic pain treatment market is segmented based on product type, indication, distribution channel, and region. Notably, the neuropathic pain segment, accounting for approximately 42.3% of the market share, is driven by factors such as the increasing prevalence of diabetes neuropathy, rising clinical trials, and significant investments in drugs. DyAnsys' FDA-approved percutaneous electrical neurostimulator (PENS) device stands as a testament to innovation in this segment.

To know more Insights: https://www.datamintelligence.com/research-report/chronic-pain-treatment-market

Geographical Penetration:

North America, with a market share of approximately 39.6% in 2022, asserts its dominance in chronic pain treatment. The region's growth is attributed to escalating research and development activities, a robust healthcare infrastructure, and favorable reimbursement systems. The approval of Nevro Corporation's Senza HFX iQ spinal cord stimulation system further solidifies North America's position in advancing cutting-edge treatments for chronic pain.

Competitive Landscape:

Major global players driving the market include Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Sanofi SA, Teva Pharmaceutical Industries Ltd, Baxter International, Merck & Co. Inc, and Boston Scientific Corporation, among others.

By Product Type:

Drugs:
Opioids
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Anticonvulsants
Antidepressants
Others

Devices:
Neurostimulation Device
Analgesic Infusion
Ablation Devices

By Indication:
Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer
Migraine
Others

By Distribution Channel:
Hospitals
Clinics
Ambulatory Surgical Centers

By Region

North America:
U.S.
Canada
Mexico

Europe:
Germany
U.K.
France
Italy
Spain
Rest of Europe

South America:
Brazil
Argentina
Rest of South America

Asia-Pacific:
China
India
Japan
Australia
Rest of Asia-Pacific
Middle East and Africa

In conclusion, the global chronic pain treatment market is set for a paradigm shift, driven by technological innovations, clinical advancements, and strategic collaborations. The forecast period promises dynamic growth, with Asia-Pacific emerging as the fastest-growing region and North America leading the charge.

Related Reports:

Chronic Lower Back Pain Drugs Market: https://www.datamintelligence.com/research-report/chronic-lower-back-pain-drugs-market

Chronic Hemodialysis Catheter Market: https://www.datamintelligence.com/research-report/chronic-hemodialysis-catheter-market

Chronic Bronchitis Treatment Market: https://www.datamintelligence.com/research-report/chronic-bronchitis-treatment-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.